Product name: Dahurinol
Synonym name:
Catalogue No.: BP2058
Cas No.: 38908-87-1
Formula: C₃₀H₄₈O₅
Mol Weight: 488.709
Botanical Source: Cimicifugae rhizoma
Type of Compound: Triterpenoids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams
Inquire for bulk scale.


Chengdu Biopurify Phytochemicals Ltd. is a leading company in the research, development, manufacture and marketing of High Quality Phytochemicals and Extracts(especially Active Ingredients from Traditional Chinese Medicine，TCM), Natural Active Pharmaceutical Ingredients worldwide.
The main services:
A. Supply active ingredients and reference standards of TCM, from mgs to kgs scale
B. Custom extraction and purification, target Herb Active Ingredients
C. Custom synthesis and semi-synthesis for Natural Active Ingredients
D. CR(contract research), CM(contract manufacture) and PD(process development) services from lab scale, pilot scale to commercial scale(GMP is also available)
E. TCM compounds library for drug screen,more than 3000 compounds available, many of them are rare and unique.

HPLC of Dahurinol

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Dahurinol (CAS No.: 38908-87-1) is a natural compound isolated from Cimicifuga acerina, a plant of the genus Cimicifuga and has attracted widespread attention in recent years due to its potential pharmacological activity and good druggability. Plants of the genus Cimicifuga in traditional Chinese medicine have multiple effects such as regulating endocrine function and alleviating menopausal syndrome. As one of its main active ingredients, northern cimicifalin alcohol exhibits unique biological activity, especially showing significant therapeutic potential in the field of antimenopausal syndrome. This paper will systematically review the chemical structure and physicochemical properties of Becimaralol, plant origin and extraction methods, pharmacological activity, mechanism of action, druggability evaluation, and clinical application prospects, aiming to provide theoretical basis and reference for in-depth research and development of this natural product.

Chemical structure and physicochemical properties

Bei Cimicifalol has the molecular formula of C_27H_32O_8 and a molecular weight of 488.7090 Da. Its chemical structure belongs to the sesquiterpene compounds, containing multiple hydroxyl and ester groups, with a complex structure and distinct stereochemical characteristics. The LogP value of Becimicifalol is 4.5376, indicating good lipid solubility, which facilitates cell membrane penetration. Its polar surface area (TPSA) is 86.9900 Ų, indicating moderate polarity in vivo that facilitates binding to target proteins. Its low water solubility (0.0052 mg/mL) somewhat limits its oral bioavailability, but its higher lipophilic solubility may help cross the blood-brain barrier (BBB), further confirmed by its high blood-brain barrier permeability. The hERG channel inhibition test was negative, indicating that northern cimicmarinol carries a lower risk of cardiotoxicity. The Ames test result was 0.0, indicating no significant genotoxicity and good safety.

Plant Origins and Extraction Methods

North Cimicifugol mainly comes from the Cimicifuga genus plant Cimicifuga acerina, which is distributed in the mountainous regions of northeast and southwest China and has traditionally been used to treat female endocrine disorders, relieve menopausal symptoms, and have anti-inflammatory effects. Common methods for extracting Beicimarhenol include solvent extraction, column chromatography separation, and high-performance liquid chromatography (HPLC) purification. The typical steps are as follows:

1. Raw material preparation: collect the dried above-ground parts of Cimicifuga acerina and crush them into fine powder.
2. Solvent extraction: Ethanol or methanol is used for reflux extraction, generally taking 2-3 hours, with several cycles to improve recovery rates.
3. Crude extract concentration: Concentrate the extract to an appropriate volume and perform liquid-to-liquid distribution to remove fat-soluble impurities.
4. Column chromatography separation: Separation is performed using silica gel columns or reversed-phase columns, combined with gradient elution technology, to separate components containing northern cimicmarol.
5. Purification and identification: Compound structure confirmed through HPLC purification, combined with mass spectrometry (MS), nuclear magnetic resonance (NMR), and other technologies.

This extraction process offers high extraction efficiency and purity, meeting the needs of subsequent pharmacological activity studies.

Pharmacological activity research

Research on the pharmacological activity of becimicifalol mainly focuses on its therapeutic potential for menopausal syndrome. Menopausal syndrome is an endocrine disorder caused by declining ovarian function in women, manifesting as hot flashes, mood swings, osteoporosis, and other symptoms. North cimicmarolol exerts its antimenopausal syndrome effect by regulating estrogen receptors (ER) and related hormone levels.

Antimenopausal syndrome effects

Multiple in vitro and in vivo experiments have shown that Becimarinol can significantly regulate the expression and activity of estrogen receptor α (ESR1) and estrogen receptor β (ESR2), promoting balance in estrogen signaling pathways. Additionally, northern cimicmarinol affects key targets such as sex hormone-binding globulin (SHBG), progesterone receptors (PGR), and aromatase (CYP19A1), regulating the metabolism and balance of estrogen and progesterone in the body, thereby alleviating menopausal symptoms.

Other potential pharmacological activities

In addition to preventing menopausal syndrome, Becimarhenol also exhibits anti-inflammatory, antioxidant, and neuroprotective activities. Its anti-inflammatory effect may be achieved by inhibiting the NF-κB signaling pathway and the expression of inflammatory factors; Antioxidant activity helps alleviate tissue damage related to oxidative stress; Neuroprotective effects may be related to its good blood-brain barrier penetration, offering potential for treating neurodegenerative diseases.

Mechanism of action and molecular targets

The main mechanism of action of becimicifalol involves regulation of various hormone receptors and enzymes, specifically including:

1. Estrogen receptor regulation (ESR1 and ESR2)
   North Cimichorinol can selectively regulate the expression and activity of ESR1 and ESR2, promote estrogen signaling, and restore the balance of estrogen levels in menopausal women. Activation of ESR2 is considered particularly important for alleviating menopausal symptoms, and northern cimicmarinol has strong affinity for this target, demonstrating good selectivity.

2. Sex hormone-binding globulin (SHBG) regulation
   SHBG acts as a carrier for binding sex hormones in the blood, and its levels directly affect the biological activity of free hormones. Becimicmarinol can regulate SHBG expression, indirectly modulating the availability of estrogen and progesterone in the body.

3. Aromatase (CYP19A1) inhibition
   Aromatases catalyze the conversion of androgens to estrogens and are key enzymes for estrogen synthesis. Becimarinol has a certain inhibitory effect on CYP19A1, regulates hormone synthesis balance, and prevents abnormal fluctuations in hormone levels.

4. Progesterone receptor (PGR) activation
   Activation of progesterone receptors helps regulate reproductive system function and endocrine balance. North cimicmarinol regulates PGR expression and promotes progesterone signaling, synergistically improving menopausal symptoms.

In summary, Becimarinol regulates the stability of the female endocrine system through its multi-target and multi-pathway synergistic effects, demonstrating its unique advantages as a natural antimenopausal drug.

Druggability evaluation and pharmacokinetics

The druggability parameters of northern cimicmarinol indicate that it has promising potential for drug development. Its molecular weight is 488.7090 Da, slightly above the 500 Da limit recommended by Lipinski's rules, but still within an acceptable range. The LogP value was 4.5376, indicating good lipid solubility, which facilitates cell membrane penetration and oral absorption. TPSA is 86.99 Ų, suitable for binding to protein targets while supporting good membrane permeability.

Low water solubility (0.0052 mg/mL) may limit its oral bioavailability, and solubility needs to be improved through formulation technologies such as nanocarriers and solid dispersions. The high permeability of the blood-brain barrier suggests its potential advantage in treating central nervous system diseases. hERG channels have no inhibitory effects, reducing the risk of cardiotoxicity. The Ames test was negative, indicating low genotoxicity risk and relatively high safety.

Pharmacokinetic data are still incomplete. Preliminary in vivo trials show that cimicmarthenol is well absorbed orally and widely distributed, especially at high concentrations in brain tissue. The metabolic pathway mainly involves hepatic enzyme systems, and the activity and toxicity of these metabolites require further research. Excretion is mainly completed via the kidneys, with a moderate half-life, supporting routine dosing regimens.

Prospects and outlooks for clinical applications

With the intensifying aging population, the demand for prevention and treatment of menopausal syndrome is growing. Becimarthenol, as a naturally derived multi-target regulator, has good safety and pharmacological activity, showing broad clinical application prospects. Its excellent blood-brain barrier permeability not only helps alleviate menopausal symptoms but may also play a role in adjunctive treatment of neurodegenerative diseases.

Future research should focus on:

1. Preclinical safety and toxicological assessment
   Systematically assess the long-term toxicity, sensitizability, and potential drug interactions of becimicifalol to provide safety assurance for clinical trials.

2. Pharmacokinetics and dosage form optimization
   Further refine pharmacokinetic parameters, develop highly effective oral formulations, and increase bioavailability and patient compliance.

3. Clinical trial design
   Conduct randomized controlled clinical trials targeting menopausal syndrome patients to verify efficacy and safety, and promote clinical translation.

4. In-depth research on multi-target mechanisms
   Using modern molecular biology and omics techniques, the comprehensive mechanisms of action of northern cimicifalol are revealed, expanding its indications.

In summary, as a natural product with high development value, Becimicmarolol is expected to become an important candidate drug for treating menopausal syndrome and related diseases in the future.

Conclusion

Beishoumarthenol, a natural sesquiterpene compound isolated from Cimicifuga acerina, demonstrates significant antimenopausal syndrome activity and multi-target regulation due to its unique chemical structure and excellent physicochemical properties. Its excellent druggability parameters and safety evaluation lay a solid foundation for drug development. Although research on its pharmacokinetics and clinical efficacy is still in its early stages, Becimicmarthenol is undoubtedly a shining new star in the field of natural product pharmacology. In the future, through multidisciplinary collaborative research, it is expected that Becinumalol will move from the laboratory to clinical practice, benefiting a wide range of menopausal women and patients with related diseases.